Novelix Pharmaceuticals Ltd
₹64.50▲ +1.09 (+1.72%)
NOVELIX·BSE·Retail
Market Cap
135.22 Cr
PE Ratio
53.31
Volume
1,618
Day High - Low
64.72 - 57.40
52W High-Low
92.00 - 49.01
₹64.50▲ +1.09 (+1.72%)
Market Cap135.22 Cr
PE Ratio53.31
Volume1,618
Day High - Low64.72 - 57.40
52W High-Low92.00 - 49.01
Novelix Pharmaceuticals Ltd (NOVELIX): company summary
The company's business is growing rapidly, with annual revenue rising 330.7% year-over-year and annual net profit jumping 3100.0%.
Novelix Pharmaceuticals Ltd (NOVELIX) is a micro-cap Retail company valued at ₹135 crore operating in Pharmacy Retail on the NSE and BSE.
- Recent price move
- Novelix Pharmaceuticals Ltd last traded at ₹64.5, modestly up 1.72% on the day.
- Financial performance
- The company's business is growing rapidly, with annual revenue rising 330.7% year-over-year and annual net profit jumping 3100.0%. The latest quarter saw revenue increase 65.1% compared to the same quarter a year earlier, while net profit surged 972.7%.
- Valuation multiples
- The stock trades at 53.3 times earnings, 3.25 times book value.
- Things to watch
- The stock is 31.1% below its 52-week high, and the company's net profit margin, though up, remains at 1.9%. The company is almost debt-free, with debt to equity at 0.09.
- Where it stands
- The company has shown strong growth in both revenue and net profit, with the latest quarter reflecting a significant increase. The stock is currently trading below its 52-week high.
Summarised by DocStoX's model on 2026-10-18 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.
DocStoX Score
2.2/10
Poor
Fair Value
Sign in to see
ROE
5.50%
Weak
P/E
53.31x
Expensive
Debt / Equity
0.09
Low
Industry
Retail
Pharmacy Retail
Overall View
Mixed
Price performance
Day₹57.40
₹64.72
52W₹49.01
₹92.00
DocStoX take
Supported by growth (9.0), but held back by valuation (0.0). Growth looks strong at 9.0, but that is offset by valuation at 0.0 and quality at 0.2 and momentum at 3.0. We are calling it Mixed rather than resolving the conflict for you.
DocStoX score
Low confidence2.2
/10
Poor
Quality
Weak
ROE 5.5%
Valuation
Expensive
P/E 53.3×
Growth
Strong
Revenue +165.7% 5Y CAGR
Risk
Moderate
D/E 0.09
Momentum
Soft
36% of 52-week range
At a glance
Market Cap
₹135 Cr
52W High / Low
₹92 / ₹49
Dividend Yield
0.00%
Promoter Holding
50.57%
EPS (TTM)
₹1.21
Book Value
₹22.05
Key highlights
- Revenue compounding 166% a year
- Low leverage — D/E 0.09
- Loss-making in some of the last 5 years
- Quality is weak (0.2/10)
2 Positives4 Watchouts
Growth
Financials
Technicals
Peers
News
Forecasts
About the company
More data
Filings, corporate actions and ownership detail — opened on demand.
More Retail stocks · Pharmacy Retail
Explore Novelix Pharmaceuticals Ltd’s valuation
Free deep-dive tools · no sign-up
Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.
Novelix Pharmaceuticals Ltd peers in Retail
Other Retail stocks on the NSE & BSE. See the full Retail sector list.
Related tools & concepts
Value Novelix Pharmaceuticals Ltd with the ratios and calculators DocStoX uses in its analysis.
P/E RatioPrice to earningsReturn on Equity (ROE)ProfitabilityROCECapital efficiencyDebt to EquityLeverageP/B RatioPrice to bookNet Profit MarginBottom-line efficiencyDCF / Intrinsic ValueEstimate fair valueCAGR CalculatorAnnualised returnDividend YieldIncome on pricePosition SizeRisk-based sizingBrokerage CalculatorCharges on a tradeSIP CalculatorSystematic investing